Kinnate Biopharma is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically defined vulnerabilities.

Our Pipeline

At Kinnate we design and develop selective small molecules with the mission
to provide the right drug to the right patient.


Our Team

Our team of oncology experts all have decades of experience
in successfully developing small molecule therapies.

Kinnate Team Photo

Board of Directors

A diverse blend of experience in pharmaceutical R&D,
business development and life sciences investing.


Our Scientific Advisors

A unique pairing of world-class precision medicine oncology leaders and
clinical researchers from leading institutions.



Fount Therapeutics Secures Series A Financing

April 2018

Fount Therapeutics secures $22 million Series A financing from Foresite Capital and Eshelman Ventures. The funds will establish multiple subsidiary R&D companies to develop treatments in various therapeutic areas. The first "NewCo", Kinnate, will be focused on developing precision oncology treatments. Other companies soon to follow.